Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ RH Reports First Quarter Fiscal 2026 Results (Business Wire) +++ RH Aktie +3,77%

ABBOTT LABORATORIES Aktie

 >ABT Aktienkurs 
78.02 EUR    +1.0%    (TradegateBSX)
Ask: 77.54 EUR / 90 Stück
Bid: 77.32 EUR / 90 Stück
Tagesumsatz: 2811 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
ABT Aktie über LYNX handeln
>ABT Performance
1 Woche: 0%
1 Monat: +11,5%
3 Monate: -18,3%
6 Monate: -25,6%
1 Jahr: -33,6%
laufendes Jahr: -26,3%
>ABBOTT LABORATORIES Aktie
Name:  ABBOTT LABORATORIES
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US0028241000 / 850103
Symbol/ Ticker:  ABL (Frankfurt) / ABT (NYSE)
Kürzel:  FRA:ABL, ETR:ABL, ABL:GR, NYSE:ABT
Index:  S&P500
Webseite:  https://www.abbott.com/
Profil:  Abbott Laboratories is a diversified healthcare company that discovers, develops, manufactures, and sells a comprehensive range of medical products and pharmaceuticals globally. The company operates through four primary segments: Established Pharmace..
>Volltext..
Marktkapitalisierung:  134166.7 Mio. EUR
Unternehmenswert:  157789.62 Mio. EUR
Umsatz:  38987.77 Mio. EUR
EBITDA:  9661.86 Mio. EUR
Nettogewinn:  5422.21 Mio. EUR
Gewinn je Aktie:  3.11 EUR
Schulden:  29410.57 Mio. EUR
Liquide Mittel:  5876.59 Mio. EUR
Operativer Cashflow:  8175.22 Mio. EUR
Bargeldquote:  0.4
Umsatzwachstum:  -0.19%
Gewinnwachstum:  -56.24%
Dividende je Aktie:  2.09 EUR
Dividendenrendite:  2.74%
Dividendenschätzung:  2.8%
Div. Historie:  15.04.26 - 0.53442895€
15.01.26 - 0.542178€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  ABBOTT LABORATORIES, ABBOTT LABS, ABBOTT LAB, (ABT), ABT
Letzte Datenerhebung:  12.06.26
>ABT Kennzahlen
Aktien/ Unternehmen:
Aktien: 1741.81 Mio. St.
Frei handelbar: 99.32%
Rückkaufquote: 0.37%
Mitarbeiter: 115000
Umsatz/Mitarb.: 0.33 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 30.91%
Bewertung:
KGV: 24.79
KGV lG: 16.23
KUV: 3.44
KBV: 2.98
PEG-Ratio: -
EV/EBITDA: 16.33
Rentabilität:
Bruttomarge: 52.84%
Gewinnmarge: 13.91%
Operative Marge: 17.77%
Managementeffizenz:
Gesamtkaprendite: 6.54%
Eigenkaprendite: 12.45%
 >ABT Anleihen 
>ABT Peer Group
 
11.06.26 - 01:45
Abbott (ABT) Dips More Than Broader Market: What You Should Know (Zacks)
 
In the most recent trading session, Abbott (ABT) closed at $89.17, indicating a -2.28% shift from the previous trading day....
10.06.26 - 16:45
Mounting Evidence Backs Abbott′s Cancer Diagnostics Growth Story (Zacks)
 
ABT's Exact Sciences acquisition expands its cancer diagnostics portfolio as new data and screening guidelines strengthen growth prospects....
09.06.26 - 23:48
New Investors: 3 Rock-Solid Stocks to Build Your Portfolio Around (Fool)
 
Visa, Home Depot, and Abbott Laboratories are blue chip stocks that can provide your portfolio with a good mix of safety, stability, and dividend income over the long term....
04.06.26 - 17:30
Abbott Addresses a Major Diabetes Care Gap With Tech Innovation (Zacks)
 
ABT wins the CE Mark for Libre Duo sensors that track glucose and ketones every minute, aiming to spot DKA risks earlier and reduce routine testing....
01.06.26 - 17:30
Abbott′s CE Mark Win for Libre Duo Systems May Lift Its Stock (Zacks)
 
ABT wins CE Mark for Libre Duo systems, the first dual glucose-ketone sensors, enabling real-time monitoring as European rollout begins later this year....
30.05.26 - 00:24
KBRA Assigns AA+ Rating to State of Illinois, Build Illinois Bonds (Sales Tax Revenue), Junior Obligation Series A and B of June 2026; Affirms Parity Debt; Stable Outlook (Business Wire)
 
NEW YORK--(BUSINESS WIRE)--#creditratingagency--KBRA assigns a long-term rating of AA+ with a Stable Outlook to the State of Illinois (the "State"), Build Illinois Bonds (Sales Tax Revenue Bonds), Junior Obligation Series A and B of June 2026 (the "Junior Bonds"). KBRA additionally affirms the long-term rating of AA+ with a Stable Outlook for the State's outstanding parity Junior Obligation Build Illinois Bonds. Key Credit Considerations The rating actions were because of the following key credit considerations: Credit Positives Security provisions are strong and include a priority lien on State sales tax revenues (after debt service payments on the Senior Obligation Build Illinois Bonds), a continuing appropriation requirement, and strong non-impairment language. Junior Bonds' additional bonds test (ABT) requires 10.2x coverage of MADS on combined debt outstanding, limiting the potential to overleverage. The statewide sales tax base is expansive and diverse, highlighted by combined lien debt service co...
29.05.26 - 17:00
BSX vs. ABT: Which Medical Stock Has More Upside Potential? (Zacks)
 
Boston Scientific and Abbott both posted solid quarterly growth, but analysts see stronger upside for Boston Scientific despite mounting operational pressures....
29.05.26 - 13:54
Is Abbott Laboratories Stock Underperforming the Dow? (Barchart)
 
Um den gesamten Artikel unter newsbreak.com zu lesen, klicken Sie bitte auf die Überschrift...
28.05.26 - 16:45
Is It Worth Investing in Abbott (ABT) Based on Wall Street′s Bullish Views? (Zacks)
 
According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?...
28.05.26 - 01:45
Abbott (ABT) Stock Falls Amid Market Uptick: What Investors Need to Know (Zacks)
 
Abbott (ABT) concluded the recent trading session at $85.68, signifying a -1.14% move from its prior day's close....
27.05.26 - 16:00
How Abbott′s Diagnostics Unit Is Shaping Up Through the Rest of 2026 (Zacks)
 
ABT's Diagnostics unit witnesses mixed Q1 results as Core Lab growth offsets China weakness and softer respiratory testing demand....
22.05.26 - 16:42
Abbott Laboratories Stock Is Getting Decimated, But the Smart Money Senses Opportunity (Barchart)
 
Um den gesamten Artikel unter newsbreak.com zu lesen, klicken Sie bitte auf die Überschrift...
20.05.26 - 16:01
Abbott′s Biosimilar Push to Help Sustain EPD Growth Momentum (Zacks)
 
ABT's EPD unit posts 9% Q1 sales growth as biosimilars and emerging market demand support its long-term expansion plans....
18.05.26 - 16:45
ABT vs. ZBH: Which Surgical Equipment Stock Is the Better Bet Now? (Zacks)
 
Abbott vs. Zimmer Biomet: surgical equipment stocks face diverging growth, acquisitions, and valuation shifts as investors weigh momentum and margins....
15.05.26 - 17:30
How Abbott′s Volume-Driven Nutrition Strategy Is Shaping Up (Zacks)
 
ABT shifts to a volume-led Nutrition strategy with pricing moves and new product launches after Q1 sales declined 6%....
13.05.26 - 16:00
Abbott Stock at 52-Week Low After Q1 Earnings: Book Profits or Hold? (Zacks)
 
ABT's Q1 beat was overshadowed by Exact Sciences dilution, legal risks and weak Diagnostics trends as shares hit a 52-week low....
12.05.26 - 16:45
Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic? (Zacks)
 
According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?...
11.05.26 - 19:36
Rendite auf Mehrjahreshoch: Dividendenkönig im Crash-Modus: Fallendes Messer oder Mega-Chance? (Wallstreet-Online)
 
Die Aktie von Dividendenkönig Abbott Laboratories ist in den freien Fall übergangenen, der Chart ist schrecklich, doch Bewertung und Dividende umso attraktiver....
08.05.26 - 16:00
Abbott′s Medical Device Strategy Supports Long-Term Growth Outlook (Zacks)
 
ABT's Medical Devices segment posts 8.5% Q1 growth as Electrophysiology, Rhythm Management and Heart Failure deliver strong gains....
08.05.26 - 14:54
Abbott Laboratories Stock: Analyst Estimates & Ratings (Barchart)
 
Um den gesamten Artikel unter newsbreak.com zu lesen, klicken Sie bitte auf die Überschrift...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Es liegt nun einmal in meiner Natur: ich will lieber eine Ungerechtigkeit begehen, als Unordnung ertragen. - Johann Wolfgang von Goethe
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!